Pacira Pharmaceuticals (PCRX) PT Lowered to $52 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pacira Pharmaceuticals (PCRX) PT Raised to $39 at BMO Capital on 3Q Report; 'Higher Gross Margin and Lower R&D'
November 9, 2017 9:56 AM ESTBMO Capital raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $39.00 (from $38.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes a positive outlook on the shares, as the company reported earnings per share... More
UPDATE: H.C. Wainwright Assumes Pacira Pharmaceuticals (PCRX) at Buy
November 9, 2017 7:17 AM EST(Updated - November 9, 2017 7:35 AM EST)
(updated to add analyst comment)
H.C. Wainwright assumes coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $52.00.
Analyst Oren Livnat comments "Slow and steady wins... More
Pacira Pharma (PCRX) Tops Q3 EPS by 17c, Miss on Revenues
November 8, 2017 7:37 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.11, $0.17 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $67.3 million versus the consensus estimate of $70.04 million.
... More
